Five Point Holdings LLC, an Irvine-based developer, has significantly revised its financial outlook for 2026. The company slashed its net income forecast for that year by 80%, from an earlier projection of $100 million down to $20 million. Following this announcement, shares for Five Point Holdings (NYSE: FPH) fell by nearly 8%, closing at $4.14 apiece and giving the company a market capitalization of $613 million.
The developer attributed the revised forecast to two primary factors: weakening housing demand in the current market and a strategic decision to defer certain land sales. Five Point Holdings stated its intention to avoid selling land in a less favorable market, opting instead to wait for improved conditions. This approach aims to preserve the value of its assets by delaying sales until market dynamics are more advantageous.
Another Irvine-based company, MDxHealth SA, a medical diagnostics firm, also reported challenging financial news. Shares for MDxHealth (Nasdaq: MDXH) dropped 16% to 17 cents per share, bringing its market capitalization to $17 million. This decline followed a previous fall in share value last Thursday. The company reported that its preliminary unaudited revenue for the third quarter would be flat. In conjunction with this revenue update, MDxHealth SA also suspended its annual guidance for 2026.
In contrast, Irvine-based Marwynn Holdings Inc. saw its stock rise. Shares for Marwynn Holdings (Nasdaq: MWYN) increased by 12% to $2.22 per share, resulting in a market capitalization of $43.8 million. This positive movement followed the company's announcement of a preliminary agreement with OmniX Technologies, a firm based in Singapore. The agreement focuses on exploring artificial intelligence computing services and infrastructure, specifically for use in trading securities backed by real-world assets.
Irvine mortgage lender loanDepot Inc. experienced a decline in its stock. Shares for loanDepot (NYSE: LDI) dropped 11% to 49 cents, with the company's market capitalization standing at $219 million. This decline occurred despite the company having recently announced plans to expand its use of artificial intelligence within its operations. The stock has been notably volatile, reported to be down 74% over the past six months.
Meanwhile, enVVeno Medical Corp., an Irvine-based medical device manufacturer, reported an increase in its share value. The company's stock (Nasdaq: NVNO) rose 4.8% to $8.86 apiece, establishing a market capitalization of $6 million. EnVVeno Medical recently showcased its experimental replacement venous valve at a medical conference held in Las Vegas. This presentation follows an earlier milestone this year, when the U.S. Food and Drug Administration (FDA) granted approval for the company to initiate a pivotal U.S. clinical trial for the device. EnVVeno Medical expects to commence enrolling patients in this trial during the fourth quarter of the year.
